Maryland PDAB Dossiers For Ozempic, Trulicity Accepting Comments

By Luke Zarzecki / August 29, 2025 at 6:08 PM

The Maryland Prescription Drug Affordability Board (PDAB) is requesting comments on its dossiers for Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity by Sept. 4, asking whether the two drugs have created unaffordability challenges for the state’s health care system; neither company is confirming plans to work with the board on a key concern.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.